Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Horizon Pharma Loses $11.6 Million in Second Quarter

August 31, 2011 12:07 pm | News | Comments

Horizon Pharma Inc. recorded an $11.6 million loss in the second quarter, its last quarter before the completion of an initial public offering of stock last month.


Dr. Reddy's, Pfizer Settle Lipitor Patent Lawsuit

August 31, 2011 12:02 pm | News | Comments

Dr. Reddy's Laboratories Ltd. said on Aug. 31 that it settled a lawsuit brought by Pfizer Inc. over a generic version of Pfizer's cholesterol drug Lipitor.

Drug Study Receives OK from Monitoring Board

August 31, 2011 11:58 am | News | Comments

Keryx Biopharmaceuticals Inc. said on Aug. 31 that an independent monitoring board recommended that its late-stage study of a potential colorectal cancer treatment can continue as planned until it is completed.


Computer Model Developed for Testing Heart-Disease Drugs

August 31, 2011 11:54 am | News | Comments

University of California, Davis researchers developed a computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.

Protein Thermal Shift

August 31, 2011 8:22 am | Product Releases | Comments

Life Technologies is now offering Protein Thermal Shift complete solution, an application for Applied Biosystems real-time PCR systems that enables analysis of protein thermal stability.


Two-Photon Microscopy

August 31, 2011 8:12 am | Product Releases | Comments

Special Optics offers objective lens solutions optimized for use in two-photon microscopy systems. These apochromatic objectives are customized with high numerical apertures and long working distances for use with various sample sizes and applications.


3M Licenses BART Technology

August 31, 2011 8:04 am | News | Comments

Lumora Ltd and 3M have signed a joint development and licensing agreement. Conclusion The agreement allows 3M to develop and sell nucleic acid test kits utilising Lumora’s BART technology.


New Device to Attack Heart of Tumors

August 31, 2011 7:55 am | News | Comments

Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.


COTI-2 Inhibits Cancer Cells

August 31, 2011 7:48 am | News | Comments

Critical Outcome Technologies Inc. announced recent experiments demonstrating clear evidence of COTI-2's ability to significantly inhibit the growth of cancer cells that over express Akt/Akt2, confirming it as a promising targeted therapy candidate.


Daiichi Sankyo Submits sNDA

August 31, 2011 7:34 am | News | Comments

Daiichi Sankyo Company submitted a supplemental New Drug Application for an additional indication of Diagnogreen 25 mg intravenous injection for near-infrared fluorescence angiography during cerebrovascular surgery.


Valeant Buying Afexa for $77M

August 31, 2011 7:26 am | News | Comments

Canadian drugmaker Valeant Pharmaceuticals International Inc. said it will buy cold remedy maker Afexa Life Sciences Inc. for about $77.6 million.


Analyst Upgrades Alkermes' Shares

August 31, 2011 7:22 am | News | Comments

A Caris & Co. analyst upgraded the stock of drug developer Alkermes Inc., pointing to the company's pending acquisition of a drug technology business.


Rough Start for Benlysta

August 31, 2011 7:14 am | News | Comments

A new lupus treatment developed by Human Genome Sciences Inc. is receiving a lukewarm reception from doctors so far, with demand for the drug shaping up to be much softer than expected, according to a Citi analyst.


NIH Database to Speed Research Up for Brain Injuries

August 30, 2011 12:32 pm | News | Comments

The National Institutes of Health, in partnership with the Department of Defense, is building a central database on traumatic brain injuries.


Kuros Completes Patient Recruitment for KUR-023

August 30, 2011 12:28 pm | News | Comments

Kuros Biosurgery completed patient recruitment in a clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.